International variation in physicians' attitudes towards prophylactic mastectomy - Comparison between France, Germany, the Netherlands and the United Kingdom

European Journal of Cancer

Volumn 49, Issue 13, 2013, Pages 2798-2805

  Den Heijer, M ^a   Van Asperen, C J ^b   Harris, H ^c   Nippert, I ^d   Schmidtke, J ^e   Bouhnik, A D ^f,g   Julian Reynier, C ^f,g   Evans, D G ^h   Tibben, A ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f AIX MARSEILLE UNIVERSITY   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; France; Germany; International variation; Physicians' attitudes; Prophylactic mastectomy; Surgeons; The Netherlands ; The UK

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; FEMALE; FRANCE; GENERAL PRACTITIONER; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; NETHERLANDS; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; QUESTIONNAIRE; SURGEON; UNITED KINGDOM;

BREAST CANCER; FRANCE; GERMANY; INTERNATIONAL VARIATION; PHYSICIANS' ATTITUDES; PROPHYLACTIC MASTECTOMY; SURGEONS; THE NETHERLANDS; THE UK;

ADULT; ATTITUDE OF HEALTH PERSONNEL; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; CULTURAL CHARACTERISTICS; EUROPE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LOGISTIC MODELS; MASTECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; QUESTIONNAIRES; RESIDENCE CHARACTERISTICS; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS;

EID: 84881114560     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.04.025     Document Type: Article

References (21)

1. L.C. Hartmann, D.J. Schaid, and J.E. Woods Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer N Engl J Med 340 2 1999 77 84
2. L.C. Hartmann, T.A. Sellers, and D.J. Schaid Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers J Natl Cancer Inst 93 21 2001 1633 1637
3. T.R. Rebbeck, T. Friebel, and H.T. Lynch Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group J Clin Oncol 22 6 2004 1055 1062
4. S.M. Domchek, T.M. Friebel, and C.F. Singer Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality JAMA 304 9 2010 967 975
5. C. Julian-Reynier, J. Mancini, and E. Mouret-Fourme Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations Eur J Hum Genet 19 5 2011 500 506
6. S.M. Zion, J.M. Slezak, and T.A. Sellers Reoperations after prophylactic mastectomy with or without implant reconstruction Cancer 98 10 2003 2152 2160
7. L.N. Lodder, P.G. Frets, and R.W. Trijsburg One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery) Breast Cancer Res Treat 73 2 2002 97 112
8. B.A. Heemskerk-Gerritsen, C.T. Brekelmans, and M.B. Menke-Pluymers Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic Ann Surg Oncol 14 12 2007 3335 3344
9. A.N. Van Geel, C.M. Contant, R.T. Wai, P.I. Schmitz, A.M. Eggermont, and M.M. Menke-Pluijmers Mastectomy by inverted drip incision and immediate reconstruction: data from 510 cases Ann Surg Oncol 10 4 2003 389 395
10. E.J. Meijers-Heijboer, L.C. Verhoog, and C.T. Brekelmans Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation Lancet 355 9220 2000 2015 2020
11. K.A. Metcalfe, D. Birenbaum-Carmeli, and J. Lubinski International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers Int J Cancer 122 9 2008 2017 2022
12. C.M. Julian-Reynier, L.J. Bouchard, and D.G. Evans Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women Cancer 92 4 2001 959 968
13. K.A. Metcalfe, P. Ghadirian, and B. Rosen Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation Open Med 1 2 2007 e92 e98
14. M.D. Schwartz, C. Lerman, and B. Brogan Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients J Clin Oncol 22 10 2004 1823 1829
15. L. Bouchard, I. Blancquaert, and F. Eisinger Prevention and genetic testing for breast cancer: variations in medical decisions Soc Sci Med 58 6 2004 1085 1096
16. C. Julian-Reynier, F. Eisinger, J.P. Moatti, and H. Sobol Physicians' attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines Eur J Hum Genet 8 3 2000 204 208
17. F. Eisinger, B. Bressac, and D. Castaigne [Identification and management of hereditary predisposition to cancer of the breast and the ovary (update 2004)] Identification et prise en charge des predispositions hereditaires aux cancers du sein et de l'ovaire (mise a jour 2004) Bull Cancer 91 3 2004 219 237
18. B. Meiser, C. Gaff, and C. Julian-Reynier International perspectives on genetic counseling and testing for breast cancer risk Breast Dis 27 2006 109 125
19. F. Eisinger, G. Geller, W. Burke, and N.A. Holtzman Cultural basis for differences between US and French clinical recommendations for women at increased risk of breast and ovarian cancer Lancet 353 9156 1999 919 920
20. N. Press, S. Reynolds, L. Pinsky, V. Murthy, M. Leo, and W. Burke 'That's like chopping off a finger because you're afraid it might get broken': disease and illness in women's views of prophylactic mastectomy Soc Sci Med 61 5 2005 1106 1117
21. F. Eisinger, N. Alby, and A. Bremond Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee Ann Oncol 9 9 1998 939 950